In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1435-1440

  Schwab, Ute ^a   Gilligan, Peter ^b   Jaynes, Jesse ^a   Henke, David ^b  

^a Demegen Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC PEPTIDE; ANTIINFECTIVE AGENT; METICILLIN; PROTEIN D2A21; PROTEIN D2A22; PROTEIN D4B; PROTEIN D4E; PROTEIN D4E1; PROTEIN D5C; PROTEIN D5C1; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG POTENCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OSMOLARITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 0033063075     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1435     Document Type: Article

References (23)

1. Bessalle, R., H. Haas, A. Goria, I. Shalit, and M. Fridkin. 1992. Augmentation of the antibacterial activity of magainin by positive charge chain extension. Antimicrob. Agents Chemother. 36:313-317.
2. Boman, H. G. 1991. Antibacterial peptides: key components needed in immunity. Cell 65:205-207.
3. Boucher, R. C. 1994. Human airway ion transport. Am. J. Respir. Crit. Care Med. 150:581-593.
4. Gilligan, P. H. 1991. Microbiology of airway diseases in patients with CF. Clin. Microbiol. Rev. 4:35-51.
5. Gilljam, H., A. Ellin, and B. Strandvik. 1989. Increased bronchial chloride concentration in cystic fibrosis. Scand. J. Clin. Lab. Invest. 49:121-124.
6. Goldman, M. J., G. M. Anderson, E. D. Stolzenberg, U. P. Kari, M. Zasloff, and J. M. Wilson. 1997. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
7. Jaynes, J. Personal communication.
8. Johnson, L., and R. Boucher. 1997. Toward correction of the genetic defect in cystic fibrosis, p. 239-265. In K. L. Brigham (ed.), Gene therapy for diseases of the lung. Marcel Dekker, Inc., New York, N.Y.
9. Joris, L., I. Dab, and P. M. Quinton. 1993. Elemental composition of human airway surface fluid in healthy and diseased airways. Am. Rev. Respir. Dis. 148:1633-1637.
10. Knowles, M. R., J. M. Robinson, R. E. Wood, C. A. Pue, W. M. Mentz, G. C. Wager, J. T. Gatzy, and R. C. Boucher. 1997. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J. Clin. Invest. 100:2588-2595.
11. Lawyer, C., S. Pai, M. Watabe, H. Bakir, L. Eagleton, and K. Watabe. 1996. Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. J. Antimicrob. Chemother 37:599-604.
12. Lehrer, R. I., T. Ganz, and M. E. Selsted. 1991. Defensins: endogenous antibiotic peptides of animal cells. Cell 64:229-230.
13. MacDonald, D. L., D. W. York, L., M. Jones, and M. A. Zasloff. 1997. In vitro activity of MSI-78, an analog of the frog skin antibiotic magainin vs. ofloxacin (OFX) against aerobic and anaerobic clinical isolates from hospitals throughout the United States, abstr. F-45, p. 153. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Mizgerd, J. P., L. Kobzik, A. E. Warner, and J. D. Brain. 1995. Effects of sodium concentration on human neutrophil bactericidal functions. Am. J. Physiol. 269:L388-L393.
15. Moore, G. E., and L. K. Woods. 1976. Culture media for human cells - RPMI 1603, RPMI 1634, RPMI 1640 and GEM 1717. Tissue Culture Assoc. Manual 3:503-508.
16. Moss, R. B. 1995. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin. Infect. Dis. 21:839-849.
17. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pier, G. B., M. Grout, and T. S. Zaidi. 1997. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc. Natl. Acad. Sci. USA 94:12088-12093.
19. Saiman, L., and A. Prince. 1993. Pseudomonas aeruginosa pili bind to asialo GM1 which is increased on the surface of cystic fibrosis epithelial cells. J. Clin. Invest. 92:1875-1880.
20. Schwab, U. Unpublished observations.
21. ™), abstr. F-43, p. 153. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Shafer, W. M., M. E. Shepherd, B. Boltin, L. Wells, and J. Pohl. 1993. Synthetic peptides of human lysosomal cathepsin G with potent antipseudomonal activity. Infect. Immun. 61:1900-1908.
23. Smith, J. J., S. M. Travis, E. P. Greenberg, and M. J. Welsh. 1996. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229-236.